38 results about "Sensory Discomfort" patented technology

The present invention belongs to the technical field of oral care and provides a micro-organism-preventing, anti-inflammatory and pain-stopping mouthwash and a preparation method thereof. The providedmicro-organism-preventing, anti-inflammatory and pain-stopping mouthwash comprises the following components in weight percentages: 0.01%-10% of an industrial cannabis sativa flower and leaf extract,0.01%-10% of a fresh flower extract, 3%-20% of an auxiliary agent and the balance water. The industrial cannabis sativa flower and leaf extract, fresh flower extract, auxiliary agent and water are combined, so that the mouthwash has anti-inflammatory and micro-organism-preventing effects, can clean oral cavity and protect teeth, has a significant effect on oral inflammation, and at the same time has an obvious pain-stopping effect on sensory discomfort caused by diseases of mouth ulcers, etc. By controlling a ratio of each component, the mouthwash improves the anti-inflammatory, micro-organism-preventing and pain-stopping effects.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and / or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and / or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of dermatological disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; atopic dermatitis; contact dermatitis; cholestatic itch; psoriasis; sebhorrheic dermatitis; milaria rubra; ocular pain and discomfort; heat discomfort; heat stress; flushing and / or night sweats (vasomotor symptoms); and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates skin discomfort. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy of dermatological disorders.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds with a swab to the Kiesselbach's area of the human nose will relieve the discomforts of rhinitis and other nasal cavity discomforts.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and / or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; nasal congestion and nasal obstruction; pharyngeal and esophageal discomfort; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and / or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.

The present invention relates to methods and devices for treating sensory discomfort in the upper airways of a human; treating sensory discomfort in the oropharynx of a human; alleviating pain from pharyngitis in a human; alleviating cough in a human; and ameliorating the symptoms and signs of asthma, dyspnea, sleep apnea, snoring, or chronic obstructive pulmonary disease in a human. According to the invention, an active compound is delivered, preferably selectively delivered, to the oropharynx, preferably the oropharyngeal surfaces, more preferably the lower retropalatal oropharynx (LRO) of the patient. According to the invention, the active compound is a compound of the following formula, wherein -R is C2 to C4 hydroxyalkyl or polyhydroxyalkyl.

The invention relates to a traditional Chinese medicinal composition for treating coronary disease, wherein the constituents include amomum fruit, radix adenophorae, magnolia bark, long pepper, Aristolochiaceae, arborvitae tops, spicebush root, anemarrhena rhizome, longan, licorice root and bamboo leaves, the composition can be prepared into decoction, injection, electuary, powders, capsules, pills or tablets.

The invention provides an automatically-operating stool examination instrument, which belongs to the technical field of clinical examination of medical health. The automatically-operating stool examination instrument mainly aims to overcome the problem of sensory discomfort of operating personnel caused by manually-operated stool examination in the prior art. The instrument has the following main characteristics: the instrument comprises a biological microscope, a specimen introduction device, a specific examination bidirectional slideway, a specific examination device, a glass slide device, a five-channel sampling needle and a Y-direction and Z-direction manipulator which are fixedly arranged on a base plate framework; the instrument can realize automatic sampling, slide production, automatic cleaning, automatic interpretation of specific examination results and automatic recovery of specific examination consumables; and a microscope carries out automatic scanning, automatic focusing and automatic locking of images, selectively takes textual and graphic files and prints textual and graphic examination reports. The automatically-operating stool examination instrument provided by the invention has the following characteristics: the instrument can prevent the operation personnel from direct and close contact with stool specimens, effectively prevents infection of examination personnel and occurrence of iatrogenic pollution, improves the quality of a stool smear and shortens specimen processing time. The automatically-operating stool examination instrument is mainly applied to automatic examination of conventional stool examination and colloidal-gold-process stool examination.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.

The present invention relates generally to the field of topical medical therapy, cosmetics, and toiletries. More specifically, the invention relates to the use of a solvent comprising (R)-1,2-propanediol for cooling agents, for example, (R)-2-[((1fl,2S,5R)-2-isopropyl- 5-methyl-cyclohexanecarbonyl)-arnino]-propionic acid n-propyl ester (CPS-410). The invention also relates to cooling agent compositions comprising a cooling agent and, 2-propanediol, and methods for their preparation. The invention also relates to the use of such cooling agent compositions in therapy, for example, in the treatment of sensory discomfort, especially sensory discomfort of the skin (e.g., itch). The invention also relates to the use of such cooling agent compositions in cosmetics (e.g., eye make-up products) and toiletries (e.g., after-shave lotion).

The invention discloses a preparation method of a cut nursing medical powder for treating sensory discomfort of a postoperative cut, which solves the problem of treating sensory discomfort of the postoperative cut. The preparation method is characterized by comprising the following steps: (1) extracting volatile substances from coarse powder of ivy glorybind herb roots, loose knots, Tetrapanax papyriferum and barks of himalayan coralbean for later use; (2) crushing mustard plaster powder and magnetic stone powder to fine powder for later use; (3) carrying out water extraction and alcohol precipitation on roots of Sandhill Tylophora, loofah sponge, buckeye, fructus polygoni orientalis, asterina pectinifera and coked rice sprouts, and drying to obtain an initial material; and (4) spraying the volatile substances to the initial material, adding mustard plaster powder and magnetic stone powder to uniformly stir, sieving by a 60-mesh sieve and adjusting and applying. Clinical experiments verify that the cut nursing medical powder for treating sensory discomfort of the postoperative cut provided by the invention has the characteristics of good curative effect and high safety, and is worth clinically applying and popularizing.

The invention relates to a medicine feeding device for children, in particular to a medicine feeding device for children in the pediatric department. The provided medicine feeding device for childrenin the pediatric department aims at achieving the purposes that the discomfort feeling of a medicine feeding person is avoided, medicinal juice cannot be spilled out, and not only can the amount of medicinal liquid be better controlled, but also convenience is provided for stirring the medicinal juice. The medicine feeding device for children in the pediatric department is characterized by comprising a base, a first sliding rail, a first sliding block, clamping plates, a bearing base, rubber protrusions, a butterfly bolt, a gooseneck, a placement plate, supporting rods, first clamping blocks,a cup and the like; the first sliding rail is arranged on the right side of the bottom of the base, the first sliding block is slidingly connected to the first sliding rail, and the clamping plates are connected to the left side of the bottom of the base and the bottom of the first sliding block respectively. According to the medicine feeding device for children in the pediatric department, a hoseis used for feeding medicine to a child, the defects that discomfort is caused by feeding the medicine beside a bed and the medicinal juice is easily spilled out can be overcome, the medicine feedingperson is prevented from feeling fatigue, and meanwhile, the medicinal juice can also be prevented from being spilled out. Moreover, the cup with scales is arranged, so that convenience is provided for better controlling the amount of the medicinal juice.

The present invention pertains generally to the field of coolants and medical therapy. More particularly, the present invention relates to certain anti-nociceptive agents, such as [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester, that are potent and long-acting and selectively cooling for non-keratinized epithelial tissues as compared to keratinized epithelial tissues, and are useful, for example, for the treatment of (e.g., the alleviation of symptoms of; the amelioration of) sensory discomfort of non-keratinized stratified epithelial (NKSE) tissue; and so for treatment of: sensory discomfort of an ocular surface, an eyelid, a margin of an eyelid, an anterior part of an eyeball, a conjunctiva, a lachrymal system, a pre-corneal film, or a cornea, a lining of the oral cavity, an internal portion of the lips, a pharyngeal surface, an esophageal surface, or an anogenital surface; eye discomfort, e.g., caused by extended wear of contact lenses, by eye strain and / or fatigue, by air pollutants, by excessive exposure to the sun, by conjunctivitis, by dry eye syndrome; sensory discomfort associated with oral mucositis; airway (e.g., larynx, trachea, and / or bronchi) tightness, discomfort in the airways (e.g., larynx, trachea, and / or bronchi), choking, cough, and / or dyspnea, e.g., associated with asthma and / or chronic obstructive pulmonary diseases (COPD).

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to a particular 1-di-alkyl-phosphinoyl-alkane, 1-(Diisopropyl-phosphinoyl)-nonane, referred to herein as “DIPA-1-9”. Surprisingly and unexpectedly, DIPA-1-9, is able to selectively treat (e.g., suppress) sensory discomfort arising from the lumenal epithelial lining of the pharynx and esophagus without side effects. Compared to structurally similar compounds, DIPA-1-9 did not have the problems of painful cold, stinging, or irritancy, or of adverse taste when applied in the oral cavity. To deliver the DIPA-1-9 to the lumenal epithelium of the pharynx and esophagus, an ideal formulation for delivery is a solution of DIPA-1-9 in syrup, at a concentration of 5 to 12 mg / mL and a delivery volume of less than 1 mL. The delivery unit can be a plastic vial with a design such that the syrup is poured onto the base of the tongue, next to the pillars of fauces. The DIPA-1-9 then reaches the nerve endings at the base of the epithelia and transduces signals of coolness and cold. Cooling of the pharyngeal and esophageal lining relieves discomfort and is useful for conditions such as throat irritation, pharyngitis, tonsillitis, cough, chronic cough, heartburn, chest pain, and esophagitis. Moreover, the elicitation of cooling in the pharynx and esophagus can be utilized to treat dysphagia, dyspepsia, and dyspnoea, and to enhance mucus expectoration in inflammatory airway disorders such as cystic fibrosis, asthma, and chronic obstructive pulmonary diseases (which includes bronchitis and bronchiectasis). A particularly preferred embodiment is DIPA-1-9 dissolved in a syrup vehicle in a delivery unit volume of less than 1 mL.

The present invention relates to the technical field of medical and healthcare clinical examination. A pre-treatment device for examining fecal contents, wherein the technical solution is as follows: the pre-treatment device for examining fecal contents comprises a drive means (1), a fluid storage cylinder (2), a cleaning means (3) and a stirring means (4) disposed in the fluid storage cylinder (2). The beneficial effect thereof is as follows: the processes of dilution, stirring and filtering of feces are all carried out by mechanical means, which is highly efficient and can ensure that the feces are in contact with air for aerobic respiration to cause damage or decomposition to the formed elements, thus avoiding the drawback of requiring manual operations in conventional examining devices. Moreover, after addition of water or saline, by actuating a motor A (24), the fluid storage cylinder (2) can be shaken from side to side, such that feces on sidewalls of the fluid storage cylinder (2) can be diluted more thoroughly, thus avoiding residual solidified clumps of feces from forming on the sidewalls of the fluid storage cylinder (2); and placing the feces in the fluid storage cylinder (2) prevents pungent odor of feces from affecting the human body, thus eliminating sensory discomfort for operators.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to a particular 1-di-alkyl-phosphinoyl-alkane, 1-(Diisopropyl-phosphinoyl)-nonane, referred to herein as “DIPA-1-9”. DIPA-1-9, is able to selectively treat (e.g., suppress) sensory discomfort arising from the airways without side effects. Compared to structurally similar compounds, DIPA-1-9 did not have the problems of excessive cold, stinging, or irritancy, or of adverse taste. To deliver the DIPA-1-9 to the upper airway it is formulated as a solution of DIPA-1-9 in water, a water-based solution, or syrup, at a concentration of 2 to 10 mg / mL and a delivery volume of less than 0.5 mL per unit dose. The drops of DIPA-1-9 are administered into the nasal cavity or onto the base of the tongue, next to the pillars of fauces. The DIPA-1-9 then reaches the nerve endings at the base of the epithelia and transduces signals of coolness and cold. Cooling of the upper airways relieves discomfort and is useful for conditions such as throat irritation, cough, pharyngitis, and lower airway blockage disorders. The elicitation of cooling in the upper airways can be used to control cough, to treat dyspnea, and to enhance mucus clearance in lower airway disorders such as chronic obstructive pulmonary diseases (which includes bronchitis and bronchiectasis), asthma, interstitial lung diseases, cystic fibrosis, lung fibrosis, pneumonia, and other lung disorders. The efficacy of DIPA-1-9 in treating chronic obstructive pulmonary disease is especially attractive because the four primary signs of chronic obstructive pulmonary disease, cough, excessive sputum production, dyspnea, and psychic distress from the lack of control of airway discomfort, are favorably ameliorated by topical application of DIPA-1-9 to the upper airways. This method of treating chronic obstructive pulmonary disease with a cooling agent to the upper airways has not been previously described.

The present invention provides diisopropylphosphonoalkanes as topical agents for the treatment of sensory discomfort. The present invention relates generally to the field of therapeutic compounds. More specifically, the present invention relates to certain diisopropylphosphonoalkanes as described herein: DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, which are collectively referred to herein as' DIPA compounds', as well as to the use of diisopropylphosphonoalkanes, such as diisopropylphosphonoalkanes, such as diisopropylphosphonoalkanes, such as diisopropylphosphonoalkanes. These diisopropylphosphono alkanes are useful, for example, in the treatment of disorders including sensory discomfort, skin retardation, dermatitis, ocular pain and discomfort, thermal discomfort, thermal stress, redness and / or night sweat, post-operative hypothermia, post-anesthesia shivering, fatigue, exhaustion, depression, cognitive dysfunction, and are useful for enhancing cognitive function.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein (DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”) that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; psoriasis; ocular discomfort; heat discomfort; heat stress; flushing and / or night sweats (vasomotor symptoms) in post-menopausal women; post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.